Rivaroxaban (Xarelto) and Black patients
Brand names: Xarelto
What Rivaroxaban does
Rivaroxaban is a once-daily factor Xa inhibitor. It is the most prescribed DOAC in the US and has broad approved indications including peripheral artery disease and CAD (low-dose rivaroxaban 2.5 mg BID with aspirin, per COMPASS).
What the evidence says for Black patients
ROCKET-AF (Patel et al., NEJM 2011;365:883–91) showed rivaroxaban non-inferior to warfarin for AF stroke prevention. The Black subgroup was small (~3 percent). As with apixaban, the central equity argument is that DOACs eliminate the pharmacogenomic dose-finding problem that disadvantages Black patients on warfarin.
COMPASS (Eikelboom et al., NEJM 2017;377:1319–30, PMID 28844192) established rivaroxaban 2.5 mg BID plus aspirin for stable CAD/PAD — a population where Black adults are over-represented in the disease burden. Access is again uneven: cost, prior-auth, and prescribing bias.
Head-to-head vs apixaban in real-world data suggests apixaban has lower major bleeding (Lau et al., Ann Intern Med 2022;175:1515–24). For AF, apixaban is often preferred; for PAD or stroke-risk-reduction in CAD, rivaroxaban-aspirin is the COMPASS regimen.
Common alternatives
Apixaban (lower bleeding; preferred in frail or older patients), dabigatran, edoxaban, warfarin.
Side effects
- Major bleeding
- GI bleeding — slightly higher than apixaban
- Dyspepsia
- Rare hepatotoxicity
- Andexanet alfa reversible
Factors that affect adherence
Once-daily dosing favors adherence. Must be taken with food at 15 and 20 mg doses — taking on empty stomach reduces bioavailability. Xarelto is expensive ($500+/month); copay cards and Janssen patient-assistance help.
Questions to ask your doctor
Bring this list to your next appointment.
- Is apixaban a better choice for me if I'm at elevated bleeding risk?
- Am I taking this with food as required at my dose?
- What's the reversal plan if I have a major bleed?
References
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET-AF). NEJM. 2011;365:883–891.
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). NEJM. 2017;377:1319–1330. PMID 28844192.
- Lau WCY, Torre CO, Man KKC, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban. Ann Intern Med. 2022;175:1515–1524.
- U.S. Food and Drug Administration. Xarelto (rivaroxaban) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s000lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.